Health Canada Approves Generic Versions of Ozempic, Impacting Drug Costs
Health Canada has approved two generic versions of the diabetes drug Ozempic, marking Canada as the first G7 country to do so. The patent for Ozempic, originally held by Novo Nordisk, expired in early January, allowing for the introduction of generic alternatives. The approved generics are from Dr. Reddy’s Laboratories and Canadian-based Apotex. These generic versions are expected to be significantly cheaper, potentially reducing costs for patients who currently pay high out-of-pocket expenses for the medication. Health Canada assures that these generics are pharmaceutically equivalent to the brand-name drug, maintaining safety and efficacy standards. 
